Advertisement
EXEL vs RPRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and RPRX is a Hold.
Momentum Indicator for EXEL turns positive, indicating new upward trend
EXEL saw its Momentum Indicator move above the 0 level on October 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 66 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for EXEL just turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 208 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 169 of 271 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The 10-day RSI Indicator for EXEL moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 24 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.349) is normal, around the industry mean (2.788). P/E Ratio (21.146) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (440.869).
Aroon Indicator for RPRX shows an upward move is likely
RPRX's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 30 of 50 cases over the following month. The odds of a continued upward trend are 60%.
RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 173 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 16 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 15 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.386) is normal, around the industry mean (2.788). P/E Ratio (35.989) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (133.911) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
EXEL | RPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 3 | 15 | |
SMR RATING 1..100 | 23 | 97 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 20 | 15 | |
SEASONALITY SCORE 1..100 | 50 | 35 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EXEL's Valuation (90) in the Biotechnology industry is in the same range as RPRX (91) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to RPRX’s over the last 12 months.
EXEL's Profit vs Risk Rating (3) in the Biotechnology industry is in the same range as RPRX (15) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to RPRX’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew significantly faster than RPRX’s over the last 12 months.
EXEL's Price Growth Rating (35) in the Biotechnology industry is in the same range as RPRX (36) in the Pharmaceuticals Major industry. This means that EXEL’s stock grew similarly to RPRX’s over the last 12 months.
RPRX's P/E Growth Rating (15) in the Pharmaceuticals Major industry is in the same range as EXEL (20) in the Biotechnology industry. This means that RPRX’s stock grew similarly to EXEL’s over the last 12 months.
| EXEL | RPRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 60% | 2 days ago 48% |
| Stochastic ODDS (%) | 2 days ago 59% | 2 days ago 46% |
| Momentum ODDS (%) | 4 days ago 73% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 60% |
| Advances ODDS (%) | 3 days ago 68% | 2 days ago 55% |
| Declines ODDS (%) | 25 days ago 59% | 4 days ago 49% |
| BollingerBands ODDS (%) | 2 days ago 59% | 2 days ago 60% |
| Aroon ODDS (%) | 2 days ago 62% | 2 days ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 3 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s).
- EXEL’s FA Score: 3 green, 2 red.
- RPRX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while RPRX’s TA Score has 6 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- RPRX’s TA Score: 6 bullish, 4 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +3.79% price change this week, while RPRX (@Biotechnology) price change was +2.49% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was -15.16%.
Reported Earning Dates
EXEL is expected to report earnings on Feb 09, 2027.
RPRX is expected to report earnings on Feb 16, 2027.
Industries' Descriptions
@Biotechnology (+7.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EXEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with INCY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then INCY could also see price increases.
| Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
|---|---|---|---|---|
| EXEL | 100% | -5.55% | ||
| INCY - EXEL | 51% Loosely correlated | -3.94% | ||
| MIRM - EXEL | 47% Loosely correlated | -3.54% | ||
| PTCT - EXEL | 43% Loosely correlated | -4.78% | ||
| RPRX - EXEL | 39% Loosely correlated | +0.01% | ||
| RIGL - EXEL | 37% Loosely correlated | -10.88% | ||
More | ||||
RPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | +0.01% | ||
| AXON - RPRX | 48% Loosely correlated | -9.81% | ||
| INCY - RPRX | 47% Loosely correlated | -3.94% | ||
| VRTX - RPRX | 46% Loosely correlated | -1.19% | ||
| RIGL - RPRX | 40% Loosely correlated | -10.88% | ||
| EXEL - RPRX | 39% Loosely correlated | -5.55% | ||
More | ||||